8-K
filed January 17, 2024, 6:59 PM ET
CIK 0001513818
other material
confidence high
sentiment negative
materiality 1.00
Aravive, Inc.: M&A transaction — Aravive to liquidate, delist from Nasdaq, and terminate CEO and CFO
Aravive, Inc.
- Board approved transfer of all assets via assignment for the benefit of creditors on Jan 12, 2024.
- Company will voluntarily delist from Nasdaq; Form 25 to be filed Jan 29, effective ~Feb 8.
- Deregistration with SEC via Form 15 expected ~Feb 8; company has <300 record holders.
- CEO Gail McIntyre and CFO Rudy Howard terminated Jan 17; entered separation agreements with severance.
- All five directors resigned; dissolution via Certificate of Dissolution filed with Delaware ~Jan 29.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.85
Dr. Eshelman resigned as Director at Aravive, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
(ii) Dr. Eshelman and Dr. McIntyre each provided notice of their decision to resign from the Board and all committees thereof, effective immediately after the filing of the Form 15
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.99
Rudy C. Howard was terminated as Chief Financial Officer at Aravive, Inc..
- Action
- terminated
- Role
- Chief Financial Officer
Exact text from the filing
the Company terminated the employment of each of Gail McIntrye, Ph.D., the Company’s Chief Executive Officer and Rudy C. Howard, the Company’s Chief Financial Officer, effective as of January 17, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.99
Gail McIntyre was terminated as Chief Executive Officer at Aravive, Inc..
- Action
- terminated
- Role
- Chief Executive Officer
Exact text from the filing
the Company terminated the employment of each of Gail McIntrye, Ph.D., the Company’s Chief Executive Officer and Rudy C. Howard, the Company’s Chief Financial Officer, effective as of January 17, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.98
Michael W. Rogers resigned as Director at Aravive, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On January 12, 2024, (i) Amato Giaccia, Ph.D., Peter T.C. Ho, M.D., Ph.D., John A. Hohneker, M.D., Sigurd C. Kirk and Michael W. Rogers, each provided notice of his decision to resign from the Board and all committees thereof, effective as of January 17, 2024
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.98
Amato Giaccia resigned as Director at Aravive, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On January 12, 2024, (i) Amato Giaccia, Ph.D., Peter T.C. Ho, M.D., Ph.D., John A. Hohneker, M.D., Sigurd C. Kirk and Michael W. Rogers, each provided notice of his decision to resign from the Board and all committees thereof, effective as of January 17, 2024
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.85
Gail McIntyre was appointed as Secretary and Authorized Officer at Aravive, Inc..
- Action
- appointed
- Role
- Secretary and Authorized Officer
Exact text from the filing
Dr. McIntyre’s Separation Agreement also provides that Dr. McIntyre will provide consulting services to the Company, at no further cost, as may be required in connection with the liquidation of the Company and that in such capacity, Dr. McIntyre shall serve as the Company’s Secretary and Authorized Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.98
Peter T.C. Ho resigned as Director at Aravive, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On January 12, 2024, (i) Amato Giaccia, Ph.D., Peter T.C. Ho, M.D., Ph.D., John A. Hohneker, M.D., Sigurd C. Kirk and Michael W. Rogers, each provided notice of his decision to resign from the Board and all committees thereof, effective as of January 17, 2024
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.98
John A. Hohneker resigned as Director at Aravive, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On January 12, 2024, (i) Amato Giaccia, Ph.D., Peter T.C. Ho, M.D., Ph.D., John A. Hohneker, M.D., Sigurd C. Kirk and Michael W. Rogers, each provided notice of his decision to resign from the Board and all committees thereof, effective as of January 17, 2024
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.98
Sigurd C. Kirk resigned as Director at Aravive, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On January 12, 2024, (i) Amato Giaccia, Ph.D., Peter T.C. Ho, M.D., Ph.D., John A. Hohneker, M.D., Sigurd C. Kirk and Michael W. Rogers, each provided notice of his decision to resign from the Board and all committees thereof, effective as of January 17, 2024
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.9
Gail McIntyre resigned as Director at Aravive, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
(ii) Dr. Eshelman and Dr. McIntyre each provided notice of their decision to resign from the Board and all committees thereof, effective immediately after the filing of the Form 15
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Aravive, Inc. completed a disposition involving Aravive (assignment for the benefit of creditors), LLC (closed 2024-01-17).
- Action
- disposition
- Counterparty
- Aravive (assignment for the benefit of creditors), LLC
- Closing
- 2024-01-17
Exact text from the filing
y’s assets through an assignment for the benefit of creditors was in the best interest of the Company, and (ii) authorized the Company to enter into a general assignment for the benefit of creditors (the “Assignment Agreement”), by and between the Company and Aravive (assignment for the benefit of creditors), LLC, a California limited liability company (the “Assignee”), which provides for the transfer of all or substantially all of the Company’s assets to the Assignee (the “Assignment”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.7
Aravive, Inc. entered into Assignment Agreement with Aravive (assignment for the benefit of creditors), LLC (effective 2024-01-17).
- Action
- entry
- Counterparty
- Aravive (assignment for the benefit of creditors), LLC
- Effective
- 2024-01-17
Exact text from the filing
the transfer of all or substantially all of the Company’s assets through an assignment for the benefit of creditors was in the best interest of the Company, and (ii) authorized the Company to enter into a general assignment for the benefit of creditors (the “Assignment Agreement”), by and between the Company and Aravive (assignment for the benefit of creditors), LLC, a California limited liability company (the “Assignee”), which provides for the transfer of all or substantially all of the Company’s assets to the Assignee (the “Assignment”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.